Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 17, Number 8—August 2011

Research

Novel Surveillance Network for Norovirus Gastroenteritis Outbreaks, United States1

Everardo Vega, Leslie Barclay, Nicole Gregoricus, Kara Williams, David Lee, and Jan VinjéComments to Author 
Author affiliations: Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Vega, L. Barclay, N. Gregoricus, J. Vinjé); Atlanta Research and Education Foundation, Decatur, Georgia, USA (K. Williams, D. Lee)

Suggested citation for this article

Abstract

CaliciNet, the outbreak surveillance network for noroviruses in the United States, was launched in March 2009. As of January 2011, twenty state and local health laboratories had been certified to submit norovirus sequences and epidemiologic outbreak data to CaliciNet. During the network’s first year, 552 outbreaks were submitted to CaliciNet, of which 78 (14%) were associated with foodborne transmission. A total of 395 (72%) outbreaks were typed as GII.4, of which 298 (75%) belonged to a new variant, GII.4 New Orleans, which first emerged in October 2009. Analysis of the complete capsid and P2 region sequences confirmed that GII.4 New Orleans is distinct from previous GII.4 variants, including GII.4 Minerva (2006b).

Noroviruses are the primary cause of epidemic viral gastroenteritis and the leading cause of foodborne outbreaks in the United States (13). Although the course of disease is in most cases self-limiting, young, elderly, and immunocompromised persons are at risk for complications caused by severe vomiting and diarrhea (48). In addition to the clinical impact of norovirus disease, the economic effects in lost wages, time, and intervention procedures (e.g., clean-up costs and recalls) can be significant (911). Although norovirus outbreaks occur year-round, they are more common during the winter months (1214).

Noroviruses are genetically classified into 5 genogroups, GI–GV, with GI and GII strains responsible for most human disease (2,15). GII viruses can be further divided into at least 19 genotypes, of which GII.4 is responsible for >85% of outbreaks (14,16), although other genotypes and viruses continue to circulate and cause sporadic disease in children (1719). Over the past 15 years, new GII.4 variants have been identified; several have been associated with a global increase in the number of outbreaks (15). The last pandemic GII.4 variant, GII.4 2006b or GII.4 Minerva, was identified in late 2005/early 2006 and has been the predominant outbreak strain in the United States since then. The successive displacement of GII.4 variants suggests that population immunity is driving the evolution of GII.4 viruses (20,21), and the emergence of a new variant will cause an increase in the number of outbreaks in an immunologically naive population.

It is not fully understood why some GII.4 variants become pandemic whereas others do not. The combination of novel antigenic sites in protruding regions of the capsid (centered around amino acids 295 and 396) and the change or expansion of a susceptible population may be responsible for the emergence of pandemic variants (20,22). The latter theory has been supported by the discovery that different norovirus strains may have different histo–blood group antigen (HBGA) binding patterns and that nonsecretors are not susceptible to infection with certain genotypes or variants (23). Most mutations between genotypes and variants occur in the P2 region of the major capsid viral protein (VP), VP1, which contains the HBGA binding sites.

Since 2008, all 50 states have had the laboratory capacity for norovirus testing; the Centers for Disease Control and Prevention (CDC) National Calicivirus Laboratory (NCL) provides laboratory support to states that do not have in-house capacity for norovirus strain typing. Recent studies on the molecular epidemiology of norovirus in the US have been based on specimens from a subset of outbreaks that were submitted to CDC (13,24,25). To enhance and harmonize norovirus outbreak surveillance, CDC and its state partners have developed a national norovirus outbreak surveillance network, CaliciNet. CaliciNet was developed to improve standardized typing of norovirus outbreaks, assist in linking geographically different clusters of norovirus illness, allow rapid classification and identification of new norovirus strains, and establish a comprehensive strain surveillance network in the United States. In this article, we describe the CaliciNet network and report first-year results, including the identification of a new GII.4 norovirus variant.

Materials and Methods

CaliciNet

CaliciNet is a novel electronic laboratory surveillance network of local and state public health laboratories in the United States, coordinated by CDC. CaliciNet participants perform molecular typing of norovirus strains by using standardized laboratory protocols for reverse transcription PCR (RT-PCR) followed by DNA sequence analysis of the amplicons. A customized CaliciNet database developed in Bionumerics version 5.1 (Applied Maths, Austin, TX, USA) includes norovirus sequence and basic epidemiologic information (Table 1), which are submitted electronically via a secure connection to the CaliciNet server at CDC. Both epidemiologic and sequence data can then be used to help link multistate outbreaks to a common source (e.g., contaminated food). To ensure high-quality data entry, submissions to the CaliciNet server are performed by certified laboratory personnel of the participating state or local health laboratories, and final quality assurance/quality control is performed at CDC.

CaliciNet certification for participants is a 2-step process that involves evaluation of data entry and analysis of sequences and a laboratory panel test. Each laboratory must pass an annual proficiency test. The laboratory certification and proficiency test consists of analyzing a panel of fecal samples by real-time RT-PCR and conventional RT-PCR analysis followed by bidirectional sequencing as described below. Certified participants are then authorized to upload norovirus outbreak data consisting of >2 samples per outbreak to the national CaliciNet database (Table 1). GII.4 sequences with >2% and 3% difference in region C or D, respectively, and >10% difference with all other noroviruses are further analyzed at CDC by amplification of the VP1 or P2 region.

Outbreaks

All outbreaks submitted to CaliciNet and the NCL from October 2009 through March 2010 were genotyped by region D analysis (26). To verify GII.4 New Orleans variants, a subset of outbreaks from CaliciNet participating laboratories and 2 specimens from each outbreak received at the NCL from October 2009 through May 2010 were analyzed by using the P2 region as described below.

Viral RNA Extraction

Viral RNA was extracted from clarified 10% fecal suspensions in phosphate-buffered saline with the MagMax-96 Viral RNA Isolation Kit (Ambion, Foster City, CA, USA) on an automated KingFisher magnetic particle processor (Thermo Fisher Scientific, Pittsburgh, PA, USA) according to the manufacturer’s instructions and eluted into 100 µL of elution buffer (10 mmol/L Tris pH 8.0 and 1 mmol/L EDTA). Extracted RNA was stored at –80°C until further use.

Real-time RT-PCR

Viral RNA was tested for GI and GII noroviruses in a duplex format by using the AgPath-ID One-Step RT-PCR Kit (Applied Biosystems, Foster City, CA, USA) on a 7500 Realtime PCR platform (Applied Biosystems). The final reaction mix of 25 µL consisted of 400 nmol/L of each oligonucleotide primer, Cog1F, Cog1R, Cog2F, and Cog2R, and 200 nmol/L of each TaqMan Probe Ring 2 (27) and Ring 1C (28) (Table 2). Cycling conditions included reverse transcription for 10 min at 45°C and denaturation for 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C.

Region D RT-PCR

The QIAGEN One-Step RT-PCR Kit (QIAGEN, Valencia, CA, USA) was used for region D amplification in a 25-µL reaction volume. RNAse Inhibitor (Applied Biosystems) was added to a final concentration of 15–20 units/reaction. Oligonucleotide primers CapD1, CapD3, and CapC were added to a final concentration of 1 µmol/L each (Table 2). RT-PCR conditions included reverse transcription at 42°C for 30 min and denaturation at 95°C for 15 min, followed by 40 cycles of 30 s at 94°C, 30 s at 40°C, and 30 s at 72°C. A final elongation step was run for 10 min at 72°C.

P2 Region Amplification

The P2 region was amplified by using the SuperScript III One-Step RT-PCR with Platinum Taq High Fidelity Kit (Invitrogen, Carlsbad, CA, USA). The final reaction volume of 25 µL consisted of 4 µmol/L of EVP2F and EVP2R (Table 2). RT-PCR conditions included reverse transcription at 55°C for 30 min and denaturation at 94°C for 2 min, followed by 40 cycles of PCR at 94°C for 15 s, 55°C for 30 s, 68°C for 1 min, and a final extension step of 68°C for 5 min.

Amplification and Cloning of GII.4 New Orleans

Novel GII.4 New Orleans sequences were identified by region D sequence analysis and further analyzed by amplification of complete open reading frame 2. Extracted RNA from fecal samples underwent cDNA synthesis with a TVN-L1 primer (29) (Table 2) for 60 min at 50°C by using the Superscript III cDNA synthesis kit (Invitrogen). The reaction mixture was purified by using the DNA Clean and Concentrator-5 (Zymo Research, Orange, CA, USA). The cDNA was amplified by using oligonucleotides (0.5 µmol/L each) L1 and Cog2F (Table 2), using the Phusion PCR Kit with the addition of 3% dimethyl sulfoxide (Finnzymes, Woburn, MA, USA). PCR conditions included denaturation at 98°C for 30 s followed by 40 cycles of 98°C for 10 s, 48°C for 30 s, and 72°C for 1.5 min. A final elongation step was run at 72°C for 10 min.

PCR products of ≈2.5 kb were gel purified and cloned by using a TOPO-TA Cloning Kit (Invitrogen). Five clones of each strain were fully sequenced bidirectionally and their respective consensus sequences were submitted to GenBank. The accession no. for GII.4 New Orleans is GU445325.

DNA Sequencing

All amplicons were purified with the QIAquick Gel Extraction or PCR Purification Kits (QIAGEN) and sequenced by using the BigDye Terminator Kit version 1.1 (Applied Biosystems). Sequence reactions were cleaned up by using the BigDye Xterminator Kit (Applied Biosystems) and analyzed on a 3130XL Automated Sequencer (Applied Biosystems).

Phylogenetic Analysis

VP1 or P2 sequences were aligned by using MEGA4 software (30). Maximum-likelihood phylogenetic analysis of VP1 amino acids were run in PhyML version 3.0 (www.atgc-montpellier.fr/phyml/binaries.php) by using the LG amino acids replacement matrix (31). The initial tree was the best of 5 random trees, and branches were supported by 100 bootstrap replicates. Branches with bootstrap support <60 were collapsed. The P2 sequence of representative GII.4 variants (GII.4 NOLA, GII.4 Osaka, GII.4 Yerseke [2006a], GII.4 Minerva [2006b], and GII.4 New Orleans) were also included in the analysis. Maximum-likelihood scores were generated for all models available in jModelTest by using the Akaike information criterion or the Bayesian information criterion (32) to select the best nucleotide replacement matrix for phylogenetic analysis. A transitional model with rate variation between sites, TIM3+G, had the best maximum-likelihood scores. The custom model was then run in PhyML version 3.0 with the approximate-likelihood ratio test calculated for branch support (33).

Results

Figure 1

Thumbnail of CaliciNet participating states (gray), nonparticipating states (white), and 12 states that submitted norovirus-positive specimens to Centers for Disease Control and Prevention for P2 analysis (stars).

Figure 1. CaliciNet participating states (gray), nonparticipating states (white), and 12 states that submitted norovirus-positive specimens to Centers for Disease Control and Prevention for P2 analysis (stars).

As of February 2011, public health laboratories in 20 states have been CaliciNet certified (Figure 1); these states represent 53% of the US population (34). From the inception of CaliciNet in March 2009 through May 2010, 552 outbreaks were uploaded to the national CaliciNet database. Foodborne and person-to-person transmission were reported for 78 (14%) and 340 (62%) of the outbreaks, respectively, whereas the transmission route for the 134 remaining outbreaks was not reported.

Figure 2

Thumbnail of Gastroenteritis outbreak data submitted to CaliciNet from October 2009 through May 2010. Pie graphs represent the proportion of outbreaks reported as norovirus GII.4 New Orleans (white), norovirus GII.4 Minerva (black), and all other norovirus genotypes (gray).

Figure 2. Gastroenteritis outbreak data submitted to CaliciNet from October 2009 through May 2010. Pie graphs represent the proportion of outbreaks reported as norovirus GII.4 New Orleans (white), norovirus GII.4 Minerva (black), and...

GII.4 viruses caused 395 (73%) of the 552 outbreaks. The number of outbreaks increased from 4 in October 2009 to a peak of 110 in January 2010 and then decreased to 31 in May 2010 (Figure 2). A novel GII.4 variant (GII.4 New Orleans) was first identified in October 2009 and caused 56% of the outbreaks in November, compared with 11% caused by GII.4 Minerva. This novel variant remained the dominant strain in December 2009 and January 2010, causing 48% and 65% of the outbreaks, respectively. In February 2010, the number of outbreaks decreased to 84, but the proportion of GII.4 New Orleans outbreaks remained high (60%). In March 2010, GII.4 New Orleans accounted for 75% of the outbreaks. In April, total outbreaks decreased to 43, with 67% caused by GII.4 New Orleans and 7% by GII.4 Minerva; in May, total outbreaks were 31, with 52% caused by GII.4 New Orleans and 13% caused by GII.4 Minerva.

Figure 3

Thumbnail of Unrooted phylogenetic tree of the P2 region from all norovirus GII.4 New Orleans strains submitted to CaliciNet and identified by region D analysis from October 2009 through May 2010 (A) and of the complete major capsid protein viral protein 1 of selected norovirus GII.4 variants (B). Numbers on branches represent bootstrap support out of 100. Symbols represent GII.4 variant types (nomenclature proposed by NoroNet in parentheses): black squares, GII.4 NOLA variant; star, GII.4 New O

Figure 3. Unrooted phylogenetic tree of the P2 region from all norovirus GII.4 New Orleans strains submitted to CaliciNet and identified by region D analysis from October 2009 through May 2010 (A) and...

Figure 4

Thumbnail of Amino acid substitutions in the major capsid protein viral protein 1 of norovirus New Orleans GII.4 strains compared with recent GII.4 variants. The P2 hypervariable region is underlined. *Protruding regions and histo–blood group antigen interacting sites. Dots indicate sequence identity.

Figure 4. Amino acid substitutions in the major capsid protein viral protein 1 of norovirus New Orleans GII.4 strains compared with recent GII.4 variants. The P2 hypervariable region is underlined. *Protruding regions and...

Because region C and region D analyses are not able to differentiate genetically closely related GII.4 variants, we further analyzed the P2 region of 20 GII.4 New Orleans region D–positive strains from 4 CaliciNet states and sequenced the complete VP1 gene from a representative outbreak (Figure 3). Compared with recent GII.4 variants, GII.4 New Orleans had several amino acid substitutions, which were located near protruding regions (aa 294 and 396) and HBGA interaction sites (aa 339–341) (Figure 4).

In addition to the 20 strains from the CaliciNet-certified laboratories, the P2 region from 75 GII.4 outbreaks submitted by 12 non-CaliciNet states was sequenced (Figure 1). Of these, 72 (96%) outbreaks had P2 sequences with <2% nt difference compared with the prototype GII.4 New Orleans strain. Sequences from 3 outbreaks were closely related to a GII.4 variant first detected in Australia in 2008 (Figure 3).

Discussion

The launch of CaliciNet in March 2009 was a milestone in the surveillance of norovirus gastroenteritis in the United States. CaliciNet enables standardized genotyping of norovirus strains, comparison of sequences from outbreaks that have a common source, and identification of new strains in real-time. The usefulness of CaliciNet was demonstrated during the winter of 2009–2010 when the emergence of a new GII.4 variant (GII.4 New Orleans) was identified. This new variant caused 60% of the outbreaks and replaced GII.4 Minerva as the predominant GII.4 strain. In addition, a new GII.12 strain caused 17% of the outbreaks during the winter of 2009–2010 (35).

GII.4 New Orleans was first detected in October 2009, and the proportion of all norovirus outbreaks it caused increased gradually to >50% during the winter months. Compared with known GII.4 viruses, GII.4 New Orleans had several changes in key amino acids in the P2 region of VP1 and around the sites that have been shown to be important in HBGA binding (20). Because most GII.4 variants that have been identified since 2004 are conserved at these sites, it has been speculated that mutations that change the HBGA binding pattern would decrease the fitness of the virus (36). During the last transitional period when GII.4 Minerva (GII.4 2006b) was identified, another GII.4 variant was co-circulating (21,37).

CaliciNet uses the same software as the US bacterial enteric pathogen surveillance network (PulseNet) (38), but it is customized with plug-ins to add CaliciNet-specific functionality. CaliciNet uses sequence data, whereas PulseNet is based on pulsed-field gel electrophoresis restriction digestion patterns of bacterial enteric pathogens. Current typing regions of CaliciNet target small regions of the norovirus genome, which makes it difficult to discern closely related norovirus strains, although the implications to human health may be significant. Our data and data from other studies (39) demonstrated that P2 region analysis enables more sensitive identification of new GII.4 variant strains compared with currently used CaliciNet regions. Use of these analyses would increase the sensitivity of outbreak surveillance to track strains that are part of a single outbreak and likely to have a common source. Hence, P2 is under consideration to be included in CaliciNet.

Like CaliciNet, the Foodborne Viruses in Europe network (FBVE) uses a central database to which users can submit norovirus sequences (40). Compared with the FBVE network, CaliciNet focuses primarily on noroviruses, is not web-based, and is based on a secured network connection to CaliciNet servers at CDC where the states log on as clients, enabling them to upload, view, and query outbreak data submitted by other states. CaliciNet also organizes training workshops and sends standardized protocols and annual proficiency panels to its members. The benefit of the FBVE network is that it can be more easily expanded to include laboratories outside its network, whereas to date CaliciNet allows only participants from state and local health laboratories in the US to participate.

The success of CaliciNet in linking multistate outbreaks to a common source (e.g., contaminated food) will depend on joint efforts of state and local epidemiologists to rapidly identify the likely common source and on CaliciNet laboratories for the timely upload of outbreak sequences to the national CaliciNet database. Although CaliciNet has selected region D as its preferred sequence region, a region C and soon a P2 region sequence database will be maintained to enable exchange of information with other norovirus surveillance networks. Because the region D assay targets a genetically highly heterogeneous region of VP1, the performance of this assay will be closely monitored over time, and necessary changes will be implemented to improve assay sensitivity and specificity. Future CaliciNet expansion will include other gastroenteritis viruses, such as sapovirus and astrovirus, as well as add capability for CaliciNet members to submit fecal samples from patients involved in norovirus-negative outbreaks to CDC for further testing, including novel pathogen discovery sequencing technologies (18).

CaliciNet was launched in March 2009 and helped in the rapid identification of a new GII.4 variant. P2 analysis confirmed that this variant was divergent from previous GII.4 viruses. The widespread presence of GII.4 New Orleans across the US coupled with the decreasing prevalence of the GII.4 Minerva variant, which has been the major cause of outbreaks during 2006–2009, suggests gradual strain displacement. Data from the 2009–2010 winter season showed the importance of CaliciNet and its future potential for norovirus surveillance in the US. To enhance norovirus surveillance globally, CaliciNet will collaborate with other norovirus surveillance networks, such as ViroNet in Canada and the global norovirus network, NoroNet (15), to better predict or determine norovirus epidemiologic or outbreak trends. International surveillance of viral foodborne outbreaks is essential because of the increasing globalization of the food industry.

Additional members of the Calicivirus network who contributed data (state represented): Chao-Yang Pan, Tasha Padilla (CA); Justin Nucci, Mary-Kate Cichon (CO); Gregory Hovan (DE); Precilia Calimlim, Cheryl-Lynn Daquip (HI); Edward Simpson (IN); Amanda Bruesch, Kari Getz (ID); Jonathan Johnston, Julie Haendiges (MD); Heather Grieser, John Martha (ME); Laura Mosher (MI); Elizabeth Cebelinski (MN); Alisha M. Nadeau, Fengxiang Gao (NH); Ondrea Shone (NJ); Frederick Gentry (NM); Gino Battaglioli (NY), Eric Brandt, Rebekah Carmen, Steven York (OH); Andrea Maloney (SC); Amy M. Woron, Christina Moore (TN); Chun Wang (TX); Valarie Devlin (VT); Tim Davis, Tonya Danz, and Jose Navidad (WI).

Dr Vega is a microbiologist at the National Calicivirus Laboratory, Division of Viral Diseases, Centers for Disease Control and Prevention. His research interests are the molecular epidemiology and evolution of noroviruses.

Acknowledgments

We thank Brenda Brown, Du-Ping Zheng, Brian West, Shari Shea, and Kristy Kubota for help with the development, implementation, and maintenance of CaliciNet.

This research was partly funded by a grant from the CDC Foundation.

References

  1. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis. 2011;17:715.PubMed
  2. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med. 2009;361:177685. DOIPubMed
  3. Centers for Disease Control and Prevention. Surveillance for foodborne disease outbreaks—United States, 2006. MMWR Morb Mortal Wkly Rep. 2009;58:60915.PubMed
  4. Wilhelm CM, Hanna SL, Welch CA, Shahid H, Minnich LL, Daly SB, Viral gastroenteritis in Charleston, West Virginia, in 2007: from birth to 99 years of age. Infect Control Hosp Epidemiol. 2010;31:81621. DOIPubMed
  5. Roddie C, Paul JP, Benjamin R, Gallimore CI, Xerry J, Gray JJ, Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis. 2009;49:10618. DOIPubMed
  6. Haustein T, Harris JP, Pebody R, Lopman BA. Hospital admissions due to norovirus in adult and elderly patients in England. Clin Infect Dis. 2009;49:18902. DOIPubMed
  7. Lopman BA, Reacher MH, Vipond IB, Sarangi J, Brown DW. Clinical manifestation of norovirus gastroenteritis in health care settings. Clin Infect Dis. 2004;39:31824. DOIPubMed
  8. Rosenthal NA, Lee LE, Vermeulen BA, Hedberg K, Keene WE, Widdowson MA, Epidemiological and genetic characteristics of norovirus outbreaks in long-term care facilities, 2003–2006. Epidemiol Infect. 2011;139:28694. DOIPubMed
  9. Johnston CP, Qiu H, Ticehurst JR, Dickson C, Rosenbaum P, Lawson P, Outbreak management and implications of a nosocomial norovirus outbreak. Clin Infect Dis. 2007;45:53440. DOIPubMed
  10. Ethelberg S, Lisby M, Bottiger B, Schultz AC, Villif A, Jensen T, Outbreaks of gastroenteritis linked to lettuce, Denmark, January 2010. Euro Surveill. 2010;15:pii:19484.
  11. Lopman BA, Hall AJ, Curns A, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996 to 2007. Clin Infect Dis. 2011;52:46674. DOIPubMed
  12. Mounts AW, Ando T, Koopmans M, Bresee JS, Noel J, Glass RI. Cold weather seasonality of gastroenteritis associated with Norwalk-like viruses. J Infect Dis. 2000;181(Suppl 2):S2847. DOIPubMed
  13. Fankhauser RL, Monroe SS, Noel JS, Humphrey CD, Bresee JS, Parashar UD, Epidemiologic and molecular trends of “Norwalk-like viruses” associated with outbreaks of gastroenteritis in the United States. J Infect Dis. 2002;186:17. DOIPubMed
  14. Zheng DP, Widdowson MA, Glass RI, Vinjé J. Molecular epidemiology of genogroup II–genotype 4 noroviruses in the United States between 1994 and 2006. J Clin Microbiol. 2010;48:16877. DOIPubMed
  15. Siebenga JJ, Vennema H, Zheng DP, Vinjé J, Lee BE, Pang XL, Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001–2007. J Infect Dis. 2009;200:80212. DOIPubMed
  16. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology. 2006;346:31223. DOIPubMed
  17. Svraka S, Vennema H, van der Veer B, Hedlund KO, Thorhagen M, Siebenga J, Epidemiology and genotype analysis of emerging sapovirus-associated infections across. Eur J Clin Microbiol. 2010;48:21918. DOIPubMed
  18. Finkbeiner SR, Li Y, Ruone S, Conrardy C, Gregoricus N, Toney D, Identification of a novel astrovirus (astrovirus VA1) associated with an outbreak of acute gastroenteritis. J Virol. 2009;83:108369. DOIPubMed
  19. Cunliffe NA, Booth JA, Elliot C, Lowe SJ, Sopwith W, Kitchin N, Healthcare-associated viral gastroenteritis among children in a large pediatric hospital, United Kingdom. Emerg Infect Dis. 2010;16:5562. DOIPubMed
  20. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol. 2010;8:23141. DOIPubMed
  21. Centers for Disease Control and Prevention. Norovirus activity—United States, 2006–2007. MMWR Morb Mortal Wkly Rep. 2007;56:8426.PubMed
  22. Lindesmith LC, Donaldson EF, Baric RS. Norovirus GII.4 strain antigenic variation. J Virol. 2011;85:23142. DOIPubMed
  23. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003;9:54853. DOIPubMed
  24. Fankhauser RL, Noel JS, Monroe SS, Ando T, Glass RI. Molecular epidemiology of “Norwalk-like viruses” in outbreaks of gastroenteritis in the United States. J Infect Dis. 1998;178:15718. DOIPubMed
  25. Blanton LH, Adams SM, Beard RS, Wei G, Bulens SN, Widdowson MA, Molecular and epidemiologic trends of caliciviruses associated with outbreaks of acute gastroenteritis in the United States, 2000–2004. J Infect Dis. 2006;193:41321. DOIPubMed
  26. Vinjé J, Hamidjaja RA, Sobsey MD. Development and application of a capsid VP1 (region D) based reverse transcription PCR assay for genotyping of genogroup I and II noroviruses. J Virol Methods. 2004;116:10917. DOIPubMed
  27. Trujillo AA, McCaustland KA, Zheng DP, Hadley LA, Vaughn G, Adams SM, Use of TaqMan real-time reverse transcription-PCR for rapid detection, quantification, and typing of norovirus. J Clin Microbiol. 2006;44:140512. DOIPubMed
  28. Hill VR, Mull B, Jothikumar N, Ferdinand K, Vinjé J. Norovirus detection in ground water using ultrafiltration and real-time RT-PCR. Food Environ Virol. 2011. In press. http://www.springerlink.com/content/1867-0334/2/4/
  29. Ando T, Monroe SS, Noel JS, Glass RI. A one-tube method of reverse transcription-PCR to efficiently amplify a 3-kilobase region from the RNA polymerase gene to the poly(A) tail of small round-structured viruses (Norwalk-like viruses). J Clin Microbiol. 1997;35:5707.PubMed
  30. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:15969. DOIPubMed
  31. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003;52:696704. DOIPubMed
  32. Posada D. jModelTest: phylogenetic model averaging. Mol Biol Evol. 2008;25:12536. DOIPubMed
  33. Anisimova M, Gascuel O. Approximate likelihood-ratio test for branches: a fast, accurate, and powerful alternative. Syst Biol. 2006;55:53952. DOIPubMed
  34. US Census Bureau. Annual estimates of the resident population for the United States, regions, states, and Puerto Rico: April 1, 2000 to July 1, 2009 [cited 2010 Jun 29]. http://www.census.gov/popest/states/NST-ann-est.html
  35. Vega E, Vinjé J. Novel GII.12 norovirus strain, United States, 2009–2010. Emerg Infect Dis. 2011;17:15168.PubMed
  36. Yang Y, Xia M, Tan M, Huang P, Zhong W, Pang XL, Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol. 2010;84:9595607. DOIPubMed
  37. Rosenthal NA, Lee LE, Vermeulen BA, Hedberg K, Keene WE, Widdowson MA, Epidemiological and genetic characteristics of norovirus outbreaks in long-term care facilities, 2003–2006. Epidemiol Infect. 2011;139:28694. DOIPubMed
  38. Swaminathan B, Barrett TJ, Hunter SB, Tauxe RV. CDC PulseNet Task Force. PulseNet: the molecular subtyping network for foodborne bacterial disease surveillance, United States. Emerg Infect Dis. 2001;7:3829.PubMed
  39. Xerry J, Gallimore CI, Iturriza-Gómara M, Allen DJ, Gray JJ. Transmission events within outbreaks of gastroenteritis determined through analysis of nucleotide sequences of the P2 domain of genogroup II noroviruses. J Clin Microbiol. 2008;46:94753. DOIPubMed
  40. Koopmans M, Vennema H, Heersma H, van Strien E, van Duynhoven Y, Brown D, Early identification of common-source foodborne virus outbreaks in Europe. Emerg Infect Dis. 2003;9:113642.PubMed

Figures

Tables

Suggested citation for this article: Vega E, Barclay L, Gregoricus N, Williams K, Lee D, Vinjé J. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis [serial on the Internet]. 2011 Aug [date cited]. http://dx.doi.org/10.3201/eid1708.101837

DOI: 10.3201/eid1708.101837

1Additional members of the CaliciNet participating laboratories who contributed data are listed at the end of this article.

Top of Page

Table of Contents – Volume 17, Number 8—August 2011

Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Jan Vinjé, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G04, Atlanta, GA 30333, USA





characters(s) remaining.

Comment submitted successfully, thank you for your feedback.

Comments to the EID Editors

Please contact the EID Editors via our Contact Form.

 

Past Issues

Select a Past Issue:

World Malaria Day - April 25, 2014 - Invest in the future, defeat malaria

20th Anniversary - National Infant Immunization Week - Immunization. Power to Protect.

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO